Botox 100 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FCRU4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,997
Award facts
- Contract value 100% obligated
- $11,996.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $11,996.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 100-unit vials of BOTOX. The delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, carries no set-aside designation and represents a competitive award to a qualified vendor capable of supplying specialized pharmaceutical products to Department of Defense healthcare operations. DMS Pharmaceutical Group is performing this work at its Park Ridge facility and will deliver the product as part of its authorized supply chain responsibilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to provide comprehensive pharmaceutical supply support to military healthcare facilities worldwide. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, was awarded on November 13, 2025, and authorizes DLA to issue firm fixed-price delivery orders for branded and generic pharmaceuticals, biologics, and medical consumables. DMS Pharmaceutical Group's established performance history across multiple therapeutic categories and product lines demonstrates the company's capability to fulfill the specialized pharmaceutical requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FCRU4?
SPE2DR26FCRU4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCRU4 worth?
The government has obligated $11,997 on SPE2DR26FCRU4.
Is contract SPE2DR26FCRU4 an order under another contract?
Yes. SPE2DR26FCRU4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRU4 competed?
The extent of competition for SPE2DR26FCRU4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award